Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) shot up 14.8% during trading on Monday . The company traded as high as $0.30 and last traded at $0.28. 2,003,686 shares traded hands during trading, an increase of 272% from the average session volume of 537,916 shares. The stock had previously closed at $0.25.
A number of brokerages have recently commented on CYTX. Zacks Investment Research cut shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 20th. Maxim Group restated a “hold” rating on shares of Cytori Therapeutics in a report on Monday, December 3rd.
The stock has a market capitalization of $3.59 million, a PE ratio of -0.04 and a beta of 2.03.
An institutional investor recently raised its position in Cytori Therapeutics stock. Barclays PLC lifted its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 724.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,747 shares of the biotechnology company’s stock after purchasing an additional 87,647 shares during the quarter. Barclays PLC owned 0.76% of Cytori Therapeutics worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 3.10% of the company’s stock.
Cytori Therapeutics Company Profile (NASDAQ:CYTX)
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Further Reading: Sell-Side Analysts
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.